Skip to main content

Table 3 Adjusted treatment differences and odds ratios at week 30

From: Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

  Covariates Week 30
CT-P13 IV vs reference IFX IV CT-P13 SC vs CT-P13 IV CT-P13 SC vs reference IFX IV CT-P13 SC vs IFX IV
Change from baseline in DAS28-CRP score (95% CI) Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA − 0.107 (− 0.309; 0.095), p = 0.3012 − 0.587 (− 0.834; − 0.34), p < 0.0001 − 0.693 (− 0.993; − 0.393), p < 0.0001 − 0.578 (− 0.831; − 0.325), p < 0.0001
Change from baseline in CDAI score (95% CI) Race, baseline CDAI, anti-CPP, HAQ-DI, PADA − 1.138 (− 2.912; 0.636), p = 0.2087 − 3.551 (− 5.742; − 1.36), p = 0.0016 − 4.690 (− 7.438; − 1.942), p = 0.0009 − 3.502 (− 5.715; − 1.289), p = 0.002
Change from baseline in SDAI score (95% CI) Race, baseline SDAI, anti-CPP, HAQ-DI, PADA − 1.109 (− 2.983; 0.765), p = 0.2462 − 4.079 (− 6.411; − 1.747), p = 0.0006 − 5.188 (− 8.104; − 2.272), p = 0.0005 − 4.031 (− 6.385; − 1.677), p = 0.0008
Proportion of patients achieving a EULAR good response (CRP criteria) Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA 1.293 (0.913; 1.831), p = 0.1482 2.066 (1.389; 3.071), p = 0.0004 2.671 (1.722; 4.142), p < 0.0001 2.268 (1.556; 3.305), p < 0.0001
Proportion of patients achieving ACR20 response Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental 1.129 (0.806; 1.584), p = 0.4803 1.442 (0.765; 2.716), p = 0.2580 1.628 (0.797; 3.329), p = 0.1818 1.439 (0.763; 2.712), p = 0.261
Proportion of patients achieving ACR50 response Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental 1.133 (0.802; 1.601), p = 0.4777 1.601 (1.019; 2.514), p = 0.0414 1.814 (1.033; 3.185), p = 0.0384 1.597 (1.016; 2.51), p = 0.0429
Proportion of patients achieving ACR70 response Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental 1.256 (0.804; 1.965), p = 0.3171 1.731 (1.087; 2.758), p = 0.0211 2.176 (1.154; 4.102), p = 0.0165 1.72 (1.078; 2.746), p = 0.0231
Proportion of patients achieving DAS-28-CRP low disease activity: DAS28-CRP ≤ 3.2 Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA 1.248 (0.88; 1.771), p = 0.2137 2.097 (1.406; 3.127), p = 0.0003 2.618 (1.684; 4.07), p < 0.0001 2.273 (1.556; 3.322), p < 0.0001
Proportions of patients with DAS28-CRP remission: DAS28-CRP < 2.6 Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA 1.218 (0.822; 1.806), p = 0.3258 2.308 (1.509; 3.531), p = 0.0001 2.812 (1.747; 4.528), p < 0.0001 2.481 (1.660; 3.707), p < 0.0001
Proportion of patients achieving CDAI low disease activity: CDAI ≤ 10.0 Race, CDAI initial, anti-CPP, HAQ-DI, PADA 1.447 (1.029; 2.035), p = 0.0341 2.11 (1.427; 3.120), p = 0.0002 3.053 (1.980; 4.708), p < 0.0001 2.030 (1.312; 3.142), p = 0.0015
Proportions of patients achieving CDAI remission: CDAI ≤ 2.8 Race, CDAI initial, anti-CPP, HAQ-DI, PADA 1.291 (0.699; 2.384), p = 0.4145 1.224 (0.662; 2.263), p = 0.52 1.58 (0.679; 3.678), p = 0.2891 1.213 (0.654; 2.25), p = 0.5412
Proportion of patients achieving SDAI low disease activity: SDAI ≤ 11.0 Race, SDAI initial, anti-CPP, HAQ-DI, PADA 1.384 (0.985; 1.944), p = 0.0616 2.066 (1.392; 3.066), p = 0.0003 2.859 (1.850; 4.418), p < 0.0001 2.111 (1.383; 3.223), p = 0.0006
Proportions of patients achieving SDAI remission: SDAI ≤ 3.3 Race, SDAI initial, anti-CPP, HAQ-DI, PADA 1.337 (0.729; 2.454), p = 0.3487 1.23 (0.677; 2.233), p = 0.4967 1.644 (0.716; 3.779), p = 0.2417 1.219 (0.669; 2.219), p = 0.5179
Proportions of patients with Boolean remission PADA, CRP, age, BMI 1.824 (0.54; 6.165), p = 0.3337 2.552 (0.926; 7.034), p = 0.0704 4.655 (1.105; 19.622), p = 0.0364 2.422 (0.846; 6.938), p = 0.0997
Proportion of patients achieving HAQ MCID improvement HAQ-DI, age, SF-36 mental 1.505 (1.026; 2.208), p = 0.0370 1.549 (0.933; 2.57), p = 0.0908 2.331 (1.307; 4.158), p = 0.0043 1.67 (1.065; 2.619), p = 0.0258
  1. Anti-CCP anti-cyclic citrullinated peptide, BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28-CRP, 28-joint Disease Activity Score based on C-reactive protein, HAQ-DI Health Assessment Questionnaire–Disability Index, IFX infliximab, IV intravenous, MCID minimal clinically important difference, OR odds ratio, PADA Patient Global Assessment of Disease Activity, SC subcutaneous, SDAI Simplified Disease Activity Index